Uncontrolled developments of new blood vessels take place in cancer and many other life threatening diseases. Currently, RNA interference has boosted the therapeutic prospects for inhibiting gene expression responsible for increased and uncontrolled angiogenesis in disease conditions. Small interference RNA is a fast way for analysis of gene operations by masking their function phenotype. Angiogenesis is a complex mechanism with the involvement of many different protein factors. The application of siRNA enables the rapid analysis of different pathways and recognition of new target genes. So the Initial research on the curative effects of small interfering RNA in the angiogenesis process has demonstrated that this new class of drug takes great potential for curative innovation. There are two strategies in this regard: the use of “unmodified” or the use of “complexed”; “targeted and/or protected nucleic acids”. The major problem for the clinical use will be to control the off-targets effects and the transient property of the sequence specific effect of silencing. To tackle the targeted distribution to cells which is involved in the different stages of angiogenesis process will be another problem. This article will briefly discuss in-vitro and in-vivo “angiogenesis inhibition” related perspective in complex pathological conditions.
RNAi; Angiogenesis inhibition; siRNA, shRNA.
Irfan, M., Zafar, I., Rasheed, I., Iqbal, M.N., 2018. Role of RNAi in Inhibition of Angiogenesis: A Review. PSM Microbiol. 3(1): 24-29.
Get Article Updates